Rakovina Therapeutics Upsizes Financing to $2M to Fuel Oncology Pipeline
Rakovina Therapeutics has announced an upsized financing package totaling $2.0 million through a combination of convertible debentures and a private placement. The capital infusion is earmarked for near-term operations as the company advances its DNA damage response (DDR) cancer therapies.